0A4Y Stock Chart & Stats
$0.24
>-$0.01(-2.01%)
At close: 4:00 PM EDT
$0.24
>-$0.01(-2.01%)
Day’s Range― - ―
52-Week Range$0.22 - $3.32
Previous CloseN/A
Volume2.60K
Average Volume (3M)24.01K
Market Cap
$7.03M
Enterprise Value$1.24
Total Cash (Recent Filing)$5.88M
Total Debt (Recent Filing)$4.57M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 18, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding27,724,245
10 Day Avg. Volume5,333
30 Day Avg. Volume24,012
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside2087.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Listing Compliance And Immediate LiquidityRestoring NYSE American compliance and injecting multi-million dollar financing materially reduces near-term delisting risk and preserves access to public capital markets. That sustained market access and the strengthened equity base support continuity of clinical programs and gives management time to execute clinical milestones without immediate insolvency pressure.
Clinical Validation In Pancreatic CancerClinical signals, KOL engagement and an active Phase 2 collaboration with a large oncology partner represent durable operational progress. Positive comparative survival and peer-reviewed publications improve the program's scientific credibility and increase chances of later-stage partnerships or regulatory pathways that can materially expand commercial potential if replicated in randomized trials.
Antiviral / Biodefense Applicability And Regulatory IncentivesAmpligen's demonstrated protection in high‑containment preclinical models and orphan designations extend the program beyond oncology into biodefense and rare‑disease regulatory pathways. That diversification opens alternative government and noncommercial funding sources, accelerated approval routes, and long‑term strategic value less dependent on traditional oncology market dynamics.
Bears Say
Minimal Revenue And Persistent Cash BurnExtremely low revenue and sustained negative operating and free cash flow indicate the company is not self‑funding development and must continually access external capital. Persistent cash burn drains management focus, risks trial interruptions if funding gaps appear, and forces financing strategies that can compromise long‑term program execution and shareholder dilution outcomes.
High Dependence On Equity‑linked Financings And WarrantsFrequent use of warrant inducements, registered directs and placement agent warrants creates structural dilution and a large potential share overhang. This reliance on market financing signals the business cannot currently generate internal cash, raising ongoing dilution risk and complicating long‑term capital planning and investor alignment as future exercises may materially increase share count.
Balance‑sheet Volatility And Historical Negative EquityLarge swings from negative equity to a thin positive equity base reflect inconsistent capitalization and episodic financing dependence. Such volatility undermines creditor and investor confidence, restricts strategic optionality, and signals that absent sustained operating improvements or steady funding the company may face renewed liquidity stress or governance constraints over time.
AIM ImmunoTech News
0A4Y FAQ
What was AIM ImmunoTech’s price range in the past 12 months?
AIM ImmunoTech lowest share price was $0.22 and its highest was $3.32 in the past 12 months.
What is AIM ImmunoTech’s market cap?
AIM ImmunoTech’s market cap is $7.03M.
When is AIM ImmunoTech’s upcoming earnings report date?
AIM ImmunoTech’s upcoming earnings report date is Aug 18, 2026 which is in 12 days.
How were AIM ImmunoTech’s earnings last quarter?
Currently, no data Available
Is AIM ImmunoTech overvalued?
According to Wall Street analysts AIM ImmunoTech’s price is currently Undervalued.
Does AIM ImmunoTech pay dividends?
AIM ImmunoTech does not currently pay dividends.
What is AIM ImmunoTech’s EPS estimate?
AIM ImmunoTech’s EPS estimate is -0.17.
How many shares outstanding does AIM ImmunoTech have?
AIM ImmunoTech has 27,724,245 shares outstanding.
What happened to AIM ImmunoTech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AIM ImmunoTech?
Currently, no hedge funds are holding shares in GB:0A4Y
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
0A4Y Stock 12 Month Forecast
Average Price Target
$5.25
▲(2087.50% Upside)